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Sir,  
Concerns regarding the use of quantiFERON (QFT) in children younger than 5 years 
old include a higher rate of indeterminate results and the potentially lower sensitivity of QFT 
as a result of an impaired capacity to secrete IFN-γ in young age [1]. 
In this Journal, we recently reported that impaired cytokine responsiveness that 
resembles the concept of immunoparalysis was responsible for indeterminate QFT results in 
young children with clinical signs compatible with tuberculosis (TB) but with the final 
diagnosis of infectious diseases different from TB [2]. In our area (Ile de France, France) 
where BCG vaccination is recommended soon after birth we observed a significant 
discordance between Tuberculin-Skin Test (TST) positivity and QFT negativity in young 
children recently exposed to household TB cases.  Based on the hypothesis of imperfect QFT 
sensitivity, here cytokine/chemokine responses to Mycobacterium tuberculosis (M.tb) were 
evaluated in immunocompetent 0-5 years old TST+/QFT- contacts with the goal of improving 
QFT sensitivity. 
Among 105 consecutive 0-5 years old immunocompetent children who were referred 
to our center as recent household contacts from June 2012 to September 2014, ten had TB 
disease diagnosis based on chest x-ray abnormalities compatible with TB and favorable 
outcome on anti-TB treatment. The correlation between QFT and TST results was excellent in 
this group (QFT+/TST+=9/10, k=1, 95% CI [1 to 1]). QFT and TST results showed however a 
very poor correlation among 26 asymptomatic children with latent-TB diagnosis based on 
TST and/or QFT positivity while chest x-ray was normal (n=19/26 discordant results, k=-
0.16, 95% CI [-0.378 to +0.059]). Among discordant results, the TST+/QFT- profile was the 
most common (17/19). Cytokine/chemokine responses to M.tb were measured in 15 of these 
17 children (median age: 2y 5m, BCG vaccinated 15/15). In addition, two populations of 
reference were selected among the same series to identify biomarkers of infection and to 
3 
 
determine their cut-offs of positivity. The first population named true-positives (n=8, BCG-
vaccinated n=7/8) were age-matched (median age: 2y 3m), TST+/QFT+ infected children 
(uncomplicated thoracic TB: n=6/8, latent-TB: n=2/8). The second population named true-
negatives (n=8, BCG-vaccinated n=6/8) were age-matched (2y 9m) uninfected children with 
no clinical sign of TB, normal chest x-ray and negative results for both TST and QFT 
following an exposure to a not infectious (non-bacillary) index case. Eighteen 
cytokines/chemokines were measured in the residual plasma of the three QFT (quantiFERON-
GIT, Cellestis) tubes i.e. unstimulated, PHA-stimulated and M.tb-stimulated tubes from any 
subject as previously described [2, 3]. 
Five biomarkers showing either concentrations lying outside an interpretable range 
(IL-8, MCP-1 and MIP-1β) or similar concentrations (IL-7 and IL-12) in the 3 QFT tubes 
were excluded from analysis. In true-positives, three cytokines (IL-2, IL-5 and IL-13) and one 
chemokine (IP-10) were significantly more elevated in the M.tb peptide-stimulated opposed 
to the unstimulated (background) tubes (table 1). Receiver operating characteristics (ROC) 
curves were generated by plotting biomarker release values observed in true negatives 
(specificity) against the corresponding values in true positives (sensitivity). In agreement with 
the current literature, individual concentrations detected in the tubes containing M.tb peptides 
minus background were used for this analysis. As illustrated in figure 1A, the only IL-2, IL-5, 
IL-13 and IP-10, in addition to IFN-γ (p=0.0007), displayed a significant ability to 
discriminate between true-positives and true-negatives.  
In TST+/QFT- contacts, the IL-13 and to a lesser extent the IP-10 displayed a higher 
level of expression in the M.tb peptide-stimulated than in the background QFT tubes (Table 
1). As illustrated in figure 1B, ROC analysis confirmed that the only IL-13 and IP-10 could 
discriminate TST+/QFT- contacts from true-negatives. Note in this figure that the threshold 
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cut-off values of IL-13 and IP-10 that best discriminated true-positives and QFT+/TST- 
contacts from true-negatives (Younden’s index) were highly similar. 
The threshold values that best discriminated true-positives from true-negatives were 
used to categorize TST+/QFT- contacts as responders or non-responders. IP-10 identified eight 
(53%) and IL-13 identified ten (67%), TST+/QFT- contacts as responders. Combining IL-13 
and IP-10 increased the number of TST+/QFT- contacts classified as responders to 12/15 
(80%). IL-2 and IL-5 did not identify additional responders among IL-13 and/or IP-10 
positive TST+/QFT- contacts. 
This study provides important information regarding M.tb immunity in young children 
and may provide a preliminary basis for further improvement of immunodiagnostic tests for 
pediatric latent-TB.  
Higher susceptibility to TB in young children has been attributed to the propensity for 
infants to develop poor IFN-γ responses but relatively preserved Th2 responses to 
immunogens [4]. Solid evidence to support this hypothesis in M.tb infection is lacking. Low 
M.tb-specific IFN-γ response associated with the abundant M.tb-specific IL-13 response in 0-
5 year-old TST+/QFT- children with latent-TB (contained infection) does not support this 
dogma and fit with the most recent concept that components of a successful immune response 
to M.tb involve more than just IFN-γ and are largely unknown [5].  
As far as we know, this study is the first that has analyzed multiple cytokines with the 
goal of identifying alternative/additional cytokines that define M.tb infection selectively in 0 - 
5 year old children. Our results, showing that 8/15 TST+/QFT- children  screened positive 
with our IP-10 release assay, agree with the concept that combining IFN-γ and IP-10 testing 
may be one approach to increase the sensitivity of QFT in young children [6]. Our results also 
agree with previous studies showing an IL-13 response to M.tb peptides in pediatric TB [7-9]. 
Yet, this study first reports the potential added value of IL-13 in diagnosing M.tb infection in 
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young children. Overall, only 9/26 children with the diagnosis of latent-TB from our series 
displayed QFT positivity (sensitivity 35%). Adding the ten children with QFT negativity but 
IL-13 positivity improved sensitivity to 73%. Combining IL-13 and IP-10 further improved 
sensitivity to 81%. These results engage to further compare head to head the accuracy of IP-
10 and also of IL-13 as biomarkers with IFN-γ in large samples of healthy pediatric contacts. 
At best, these future studies should focus on the performance of these biomarkers according to 
age, TB status and BCG status to define the pediatric subgroups that could best benefit from 
this new approach. 
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Table 1: Biomarker concentrations (pg/ml) in Background and M.tb peptide-stimulated whole bloods  
 
Biomarkers 
True-negatives 
(n=8) 
True-positives  
(n=8) 
TST
+
/QFT- contacts  
(n=15) 
 Background M.tb peptides p(*) Background M.tb peptides p(*) Background M.tb peptides p(*) 
IL-2 
206 
(137-1193) 
250 
(116-706) 
0.7241 
110 
(45-233) 
3350 
(576-7152) 0.0001 
160 
(74-415) 
180 
(98-829) 
0.3445 
IL-4 
146 
(123-218) 
152 
(97-237) 
1 
76 
(50-181) 
140 
(87-321) 
0.0823 
130 
(75-456) 
137 
(87-454) 
0.3921 
IL-5 
22 
(11-37) 
24 
(17-67) 
0.6415 
15 
(8-46) 
81 
(33-4822) 0.0021 
18 
(13-67) 
20 
(15-70) 
0.1225 
IL-6 
8827 
(3164-14243) 
8492 
(1662-12523) 
0.7289 
3548 
(1552-20359) 
5849 
(3300-24632) 
0.2754 
4904 
(1184-14243) 
6066 
(1867-11235) 
0.4863 
IL-10 
186 
(126-526) 
163 
(103-221) 
0.1941 
76 
(30-376) 
80 
(32-422) 
0.7981 
128 
(80-526) 
148 
(97-337) 
0.3212 
IL-13 
47 
(27-434) 
39 
(26-429) 
0.5033 
37 
(24-58) 
579 
(172-5876) 0.0001 
24 
(18-62) 
131 
(23-247) 0.0005 
IL-17 
430 
(320-534) 
388 
(320-462) 
0.3269 
230 
(165-402) 
333 
(227-567) 
0.0623 
374 
(265-471) 
385 
(243-584) 
0.4179 
IFN-g 
134 
(91-177) 
116 
(73-240) 
0.5258 
58 
(28-154) 
1165 
(115-1872) 
0.0006 
91 
(44-584) 
93 
(68-576) 
0.3724 
TNF-a 
9039 
(1407-21766) 
8113 
(1522-19491) 
0.7241 
7224 
(1562-10555) 
10109 
(2370-20487) 
0.0684 
15220 
(540-21766) 
14770 
(348-22415) 
1 
IP-10 
705 
(425-1454) 
1202 
(484-1454) 
0.4839 
906 
(125-2785) 
17262 
(700-22657) 0.0016 
555 
(126-1929) 
3691 
(506-11870) 
0.0050 
G-CSF 
231 
(78-329) 
162 
(77-475) 
0.3241 
60 
(24-435) 
76 
(32-548) 
0.6479 
102 
(56-329) 
115 
(80-271) 
0.2649 
GM-CSF 
327 
(175-679) 
334 
(188-526) 
0.7986 
179 
(117-442) 
338 
(255-603) 
0.0210 
260 
(138-702) 
286 
(177-591) 
0.3505 
IL-1b 
5354 
(2625-8934) 
7119 
(3591-19685) 
0.3251 
2749 
(761-7380) 
5645 
(1560-21344) 
0.3814 
3310 
(353-9141) 
4580 
(2218-12873) 
0.1369 
M.tb: Mycobacterium tuberculosis .PHA : phytohemaglutinin. 
Results are given as median, (range) concentrations in pg/ml. 
p-values below 0.004 thresholds (corresponding to Bonferroni adjustment for 13 tests) are highlighted in bold. 
(*) Mann-Whitney test comparing the background value with the corresponding value observed in M.tb peptide-stimulated whole bloods.  
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Figure 1 
A: True-negatives vs true-positives  
 
     
                              
B: True-negatives vs TST+/QTF- contacts 
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